Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metabolic Syndrome (MetS): later-stage trial registry
1 of 2 indexed Metabolic Syndrome (MetS) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Metabolic Syndrome (MetS): 2 US clinical trials tracked, 1 recruiting.
Metabolic Syndrome (MetS) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Marymount University, running 1 of these trials.
Enrollment posture brief
Registry condition metabolic-syndrome-mets
OPEN 1 | RECR 50% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Metabolic Syndrome (MetS) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metabolic Syndrome (MetS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metabolic Syndrome (MetS) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma
NCT07219602
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
Marymount University
NCT07180147
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metabolic Syndrome (MetS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metabolic Syndrome (MetS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metabolic Syndrome (MetS) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Metabolic Syndrome (MetS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Marymount University sponsors the most Metabolic Syndrome (MetS) trials on record, review their full trial history before evaluating a specific study. See Marymount University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metabolic Syndrome (MetS) condition card totals 2 registered trials; most-linked intervention Obicetrapib 10 mg; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.